Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

Takuya Oda; Hazumu Nagata; Yasutaka Nakashima; Etsuro Nanishi; Yui Takada; Manao Nishimura; Eiji Kubo; Ken Hatae; Shouichi Ohga

doi:10.1016/j.jpeds.2019.06.018

Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

Takuya Oda, Hazumu Nagata, Yasutaka Nakashima, Etsuro Nanishi, Yui Takada, Manao Nishimura, Eiji Kubo, Ken Hatae, Shouichi Ohga

Research output: Contribution to journal › Article

Abstract

Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.

Original language	English
Pages (from-to)	227-230
Number of pages	4
Journal	Journal of Pediatrics
Volume	214
DOIs	https://doi.org/10.1016/j.jpeds.2019.06.018
Publication status	Published - Nov 2019

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/j.jpeds.2019.06.018

Fingerprint Dive into the research topics of 'Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease'. Together they form a unique fingerprint.

Cite this

Oda, T., Nagata, H., Nakashima, Y., Nanishi, E., Takada, Y., Nishimura, M., Kubo, E., Hatae, K., & Ohga, S. (2019). Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease. Journal of Pediatrics, 214, 227-230. https://doi.org/10.1016/j.jpeds.2019.06.018

@article{3eef03f1dbe7425aad3198f2b27b55b7,

title = "Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease",

abstract = "Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.",

author = "Takuya Oda and Hazumu Nagata and Yasutaka Nakashima and Etsuro Nanishi and Yui Takada and Manao Nishimura and Eiji Kubo and Ken Hatae and Shouichi Ohga",

year = "2019",

month = nov,

doi = "10.1016/j.jpeds.2019.06.018",

language = "English",

volume = "214",

pages = "227--230",

journal = "Journal of Pediatrics",

issn = "0022-3476",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

AU - Oda, Takuya

AU - Nagata, Hazumu

AU - Nakashima, Yasutaka

AU - Nanishi, Etsuro

AU - Takada, Yui

AU - Nishimura, Manao

AU - Kubo, Eiji

AU - Hatae, Ken

AU - Ohga, Shouichi

PY - 2019/11

Y1 - 2019/11

N2 - Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.

AB - Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85069696876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069696876&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2019.06.018

DO - 10.1016/j.jpeds.2019.06.018

M3 - Article

C2 - 31351682

AN - SCOPUS:85069696876

VL - 214

SP - 227

EP - 230

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

ER -